Endocrinologic Aspects of Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a chronic skin condition with unclear origins. Prior research has shown that HS often flares before menstruation and improves during pregnancy. These observations suggest a potential hormonal influence. Female predominance in HS cases also hints at a hormonal component. Obesity is a known risk factor for HS, linking it to metabolic conditions. Comorbidities like diabetes and polycystic ovarian syndrome are frequently reported. The role of androgens remains speculative but is supported by some clinical responses to antiandrogen therapy. No prior work has definitively established hormonal dysregulation as a cause of HS.

This review aims to explore the hormonal and metabolic factors possibly involved in hidradenitis suppurativa. The authors focus on patterns such as premenstrual flares and female predominance. They seek to clarify whether androgens or other hormones contribute to HS. The study also examines the link between HS and metabolic conditions like obesity. The goal is to assess whether hormonal dysregulation could be a contributing factor. The authors highlight the need for more research to confirm these associations. They aim to synthesize existing evidence on endocrine influences in HS. The review proposes that hormonal factors may play a role in disease progression.

The authors conducted a literature review to analyze hormonal and metabolic aspects of HS. They examined clinical observations such as premenstrual flare-ups and pregnancy-related improvements. They reviewed responses to antiandrogen therapy in HS patients. The study also considered comorbid conditions like diabetes and polycystic ovarian syndrome. The authors synthesized findings on the timing of HS onset relative to puberty. They evaluated the relationship between obesity and HS severity. The review did not include original data but focused on existing studies. The authors concluded that more research is needed to clarify hormonal involvement.

HS is associated with premenstrual flares and female predominance. The condition often improves during pregnancy, suggesting hormonal influence. Antiandrogen therapy has shown positive effects in some HS patients. HS typically begins years after puberty, hinting at a metabolic component. Obesity is a major contributor to HS pathogenesis. Comorbidities like diabetes and polycystic ovarian syndrome are common. The review found no definitive evidence of hormonal dysregulation as a cause. The authors propose that hormonal and metabolic factors may interact in HS development.

The authors suggest that hormonal influences may contribute to HS, based on clinical observations. They note that antiandrogen therapy can improve symptoms in some patients. The review highlights the need for further studies on hormonal dysregulation. The timing of HS onset after puberty suggests a possible metabolic disorder. Obesity and related conditions like diabetes are strongly linked to HS. The authors emphasize that the role of hormones remains unclear. They propose that more evidence is needed to confirm hormonal involvement. The review concludes that hormonal and metabolic factors warrant further investigation.